---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-002831"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:03:03.364443+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kyverna outlines 2025 priorities; pivotal SPS trial 40% enrolled, BLA filing targeted for 2026

## Summary
- 40% enrolled in pivotal Phase 2 KYV-101 trial for stiff person syndrome; BLA filing targeted for 2026.
- Cash runway into 2027 with $321.6M cash and securities as of Sep 30, 2024.
- Myasthenia gravis: confirm registrational path 1H 2025, interim Phase 2 data 2H 2025.
- Lupus nephritis: Phase 1 data expected 2H 2025; KYV-102 IND filing 2H 2025.
- Company pivoting to late-stage development and commercialization with CD19 CAR T construct KYV-101.

## SEC filing metadata
- accession: 0001213900-25-002831
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000121390025002831/0001213900-25-002831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000121390025002831/ea0227480-8k_kyverna.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-002831
- JSON: https://secwatch.observer/filing/0001213900-25-002831.json
- Plain text: https://secwatch.observer/filing/0001213900-25-002831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.